Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis
- PMID: 31954206
- DOI: 10.1016/j.jhep.2019.12.021
Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis
Abstract
Background & aims: Spontaneous portosystemic shunts (SPSS) frequently develop in liver cirrhosis. Recent data suggested that the presence of a single large SPSS is associated with complications, especially overt hepatic encephalopathy (oHE). However, the presence of >1 SPSS is common. This study evaluates the impact of total cross-sectional SPSS area (TSA) on outcomes in patients with liver cirrhosis.
Methods: In this retrospective international multicentric study, CT scans of 908 cirrhotic patients with SPSS were evaluated for TSA. Clinical and laboratory data were recorded. Each detected SPSS radius was measured and TSA calculated. One-year survival was the primary endpoint and acute decompensation (oHE, variceal bleeding, ascites) was the secondary endpoint.
Results: A total of 301 patients (169 male) were included in the training cohort. Thirty percent of all patients presented with >1 SPSS. A TSA cut-off of 83 mm2 was used to classify patients with small or large TSA (S-/L-TSA). Patients with L-TSA presented with higher model for end-stage liver disease score (11 vs. 14) and more commonly had a history of oHE (12% vs. 21%, p <0.05). During follow-up, patients with L-TSA experienced more oHE episodes (33% vs. 47%, p <0.05) and had lower 1-year survival than those with S-TSA (84% vs. 69%, p <0.001). Multivariate analysis identified L-TSA (hazard ratio 1.66; 95% CI 1.02-2.70, p <0.05) as an independent predictor of mortality. An independent multicentric validation cohort of 607 patients confirmed that patients with L-TSA had lower 1-year survival (77% vs. 64%, p <0.001) and more oHE development (35% vs. 49%, p <0.001) than those with S-TSA.
Conclusion: This study suggests that TSA >83 mm2 increases the risk for oHE and mortality in patients with cirrhosis. Our results support the clinical use of TSA/SPSS for risk stratification and decision-making in the management of patients with cirrhosis.
Lay summary: The prevalence of spontaneous portosystemic shunts (SPSS) is higher in patients with more advanced chronic liver disease. The presence of more than 1 SPSS is common in advanced chronic liver disease and is associated with the development of hepatic encephalopathy. This study shows that total cross-sectional SPSS area (rather than diameter of the single largest SPSS) predicts survival in patients with advanced chronic liver disease. Our results support the clinical use of total cross-sectional SPSS area for risk stratification and decision-making in the management of SPSS.
Keywords: ACLF; Acute decompensation; Acute-on-chronic liver failure; Ascites; Cirrhosis; Computed tomography; Hepatic encephalopathy; Liver; Portal hypertension; SPSS; Spontaneous portosystemic shunt; TIPS.
Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of Interest MP Sponsored lectures: Gore; AZ Sponsored lectures: Gilead, Abbvie, Norgine, Grifols, Bayer, Gore, BMS; AD Sponsored lectures: Bayer; WL Grants: Boston Scientific, Consultant: Boston Scientific, Abbvie, Gilead, Norgine, Gore; VLM Grants: Gilead Sciences research Scholar Program, Consultant: Gore, Sponsored lectures (National or International): Gore, Abbvie, Alfa-sigma; CR Grant: Schweine Stiftung; VHG Sponsored lectures (National or International): GORE; TR Grants: Abbvie, Boehringer Ingelheim, Gilead, MSD, Philips Healthcare, Gore; Consultant: Abbvie, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, Siemens; Sponsored lectures (National or International): Abbvie, Gilead, Gore, Intercept, Roche, MSD; AA Grants: Gilead Sciences, Consultant: AbbVie, Gilead Sciences, Gore, Griffols, Intercept Pharmaceuticals, Pfizer and Merck & Co., Sponsored lectures (National or International): AbbVie, Gilead Sciences, Gore, Griffols, Intercept Pharmaceuticals, Pfizer and Merck & Co.; EAT Consultant: Pfizer, Intercept, Gilead, Promethera, Astra Zeneca; JT Grants: Gore, Consultant: Martins Pharma, Ironwood, Gore, Alexion, BMS, Grifols, Sequana Medicals, Versantis, Sponsored lectures (National or International): Gilead, Gore, Alexion, BMS, Grifols, Sequana Medicals, Norgine, Intercept. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
Definition of SPSS: we need to speak the same language.J Hepatol. 2020 Aug;73(2):463-464. doi: 10.1016/j.jhep.2020.03.012. Epub 2020 May 21. J Hepatol. 2020. PMID: 32448470 No abstract available.
-
Reply to: "Definition of SPSS: we need to speak the same language": Computer-assisted image processing for better quantification.J Hepatol. 2020 Aug;73(2):464-465. doi: 10.1016/j.jhep.2020.04.012. Epub 2020 May 26. J Hepatol. 2020. PMID: 32471728 No abstract available.
Similar articles
-
Association between non-variceal spontaneous portosystemic shunt and outcomes after TIPS in cirrhosis.Dig Liver Dis. 2018 Dec;50(12):1315-1323. doi: 10.1016/j.dld.2018.05.022. Epub 2018 Jun 5. Dig Liver Dis. 2018. PMID: 29960900
-
Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis.Gastroenterology. 2018 May;154(6):1694-1705.e4. doi: 10.1053/j.gastro.2018.01.028. Epub 2018 Jan 31. Gastroenterology. 2018. PMID: 29360462
-
Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis.J Hepatol. 2024 Apr;80(4):596-602. doi: 10.1016/j.jhep.2023.11.033. Epub 2023 Dec 13. J Hepatol. 2024. PMID: 38097113
-
The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension.J Clin Gastroenterol. 2007 Nov-Dec;41 Suppl 3:S344-51. doi: 10.1097/MCG.0b013e318157e500. J Clin Gastroenterol. 2007. PMID: 17975487 Review.
-
Spontaneous porto-systemic shunts in liver cirrhosis: Clinical and therapeutical aspects.World J Gastroenterol. 2020 Apr 21;26(15):1726-1732. doi: 10.3748/wjg.v26.i15.1726. Epub 2020 Apr 14. World J Gastroenterol. 2020. PMID: 32351289 Free PMC article. Review.
Cited by
-
TIPS and hepatic encephalopathy in patients with cirrhosis.Metab Brain Dis. 2025 Feb 4;40(2):117. doi: 10.1007/s11011-025-01541-w. Metab Brain Dis. 2025. PMID: 39903376 Review.
-
Functional recovery from refractory hepatic encephalopathy following angiographic obliteration of a large, spontaneous portal-umbilical portosystemic shunt: a case report.CVIR Endovasc. 2022 Aug 24;5(1):45. doi: 10.1186/s42155-022-00320-3. CVIR Endovasc. 2022. PMID: 36002541 Free PMC article.
-
Portal Venous Remodeling Determines the Pattern of Cirrhosis Decompensation: A Systems Analysis.Clin Transl Gastroenterol. 2023 Sep 1;14(9):e00590. doi: 10.14309/ctg.0000000000000590. Clin Transl Gastroenterol. 2023. PMID: 37092902 Free PMC article.
-
Shunt-Induced Hepatic Encephalopathy in TIPS: Current Approaches and Clinical Challenges.J Clin Med. 2020 Nov 23;9(11):3784. doi: 10.3390/jcm9113784. J Clin Med. 2020. PMID: 33238576 Free PMC article. Review.
-
Evaluation of the Efficacy and Safety of Transjugular Intrahepatic Portosystemic Shunt Combined With Concurrent Antegrade Embolization of Large Spontaneous Portosystemic Shunts.J Med Imaging Radiat Oncol. 2025 Mar;69(2):228-236. doi: 10.1111/1754-9485.13832. Epub 2025 Feb 21. J Med Imaging Radiat Oncol. 2025. PMID: 39981811 Free PMC article.